Literature DB >> 25541282

Monitoring of autophagy is complicated--salinomycin as an example.

Jaganmohan Reddy Jangamreddy1, Soumya Panigrahi2, Marek J Łos3.   

Abstract

Monitoring of autophagy is challenging because of its multiple steps and lack of single befitting technique for a complete mechanistic understanding, which makes the task complicated. Here, we evaluate the functionality of autophagy triggered by salinomycin (anti-cancer stem cell agent) using flow cytometry and advanced microscopy. We show that salinomycin does induce functional autophagy at lower concentrations and such a dose is cell type-dependent. For example, PC3 cells show active autophagic flux at 10 μM concentration of salinomycin while murine embryonic fibroblasts already show an inhibition of flux at such doses. A higher concentration of salinomycin (i.e. 30 μM) inhibits autophagic flux in both cell types. The data confirms our previous findings that salinomycin is an inducer of autophagy, whereas autophagic flux inhibition is a secondary response.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autophagic flux; GFP-LC3; Salinomycin; Vacuolization; mTandem GFP-RFP LC3; p62/SQSTRM1

Mesh:

Substances:

Year:  2014        PMID: 25541282     DOI: 10.1016/j.bbamcr.2014.12.022

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Sulfuretin protects hepatic cells through regulation of ROS levels and autophagic flux.

Authors:  Yu-Ting Lu; Yu-Feng Xiao; Yu-Feng Li; Jia Li; Fa-Jun Nan; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2018-12-18       Impact factor: 6.150

2.  Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.

Authors:  Yismeilin R Feliz-Mosquea; Ashley A Christensen; Adam S Wilson; Brian Westwood; Jasmina Varagic; Giselle C Meléndez; Anthony L Schwartz; Qing-Rong Chen; Lesley Mathews Griner; Rajarshi Guha; Craig J Thomas; Marc Ferrer; Maria J Merino; Katherine L Cook; David D Roberts; David R Soto-Pantoja
Journal:  Breast Cancer Res Treat       Date:  2018-07-28       Impact factor: 4.872

Review 3.  Autophagy and Tubular Cell Death in the Kidney.

Authors:  Andrea Havasi; Zheng Dong
Journal:  Semin Nephrol       Date:  2016-05       Impact factor: 5.299

4.  Salinomycin co-treatment enhances tamoxifen cytotoxicity in luminal A breast tumor cells by facilitating lysosomal degradation of receptor tyrosine kinases.

Authors:  Ann-Katrin Sommer; Adam Hermawan; Frauke Martina Mickler; Bojan Ljepoja; Pjotr Knyazev; Christoph Bräuchle; Axel Ullrich; Ernst Wagner; Andreas Roidl
Journal:  Oncotarget       Date:  2016-08-02

5.  Salinomycin inhibits cholangiocarcinoma growth by inhibition of autophagic flux.

Authors:  Johannes Klose; Engin Guerlevik; Tina Trostel; Florian Kühnel; Thomas Schmidt; Martin Schneider; Alexis Ulrich
Journal:  Oncotarget       Date:  2017-12-16

6.  Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.

Authors:  Elaine A Dunlop; Charlotte E Johnson; Marie Wiltshire; Rachel J Errington; Andrew R Tee
Journal:  Oncotarget       Date:  2017-07-25

Review 7.  Salinomycin, as an autophagy modulator-- a new avenue to anticancer: a review.

Authors:  Jiang Jiang; Hailong Li; Eskandar Qaed; Jing Zhang; Yushu Song; Rong Wu; Xinmiao Bu; Qinyan Wang; Zeyao Tang
Journal:  J Exp Clin Cancer Res       Date:  2018-02-13

Review 8.  Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.

Authors:  Dan Qi; Yunyi Liu; Juan Li; Jason H Huang; Xiaoxiao Hu; Erxi Wu
Journal:  Med Res Rev       Date:  2021-11-16       Impact factor: 12.388

9.  Glucose starvation-mediated inhibition of salinomycin induced autophagy amplifies cancer cell specific cell death.

Authors:  Jaganmohan R Jangamreddy; Mayur V Jain; Anna-Lotta Hallbeck; Karin Roberg; Kourosh Lotfi; Marek J Łos
Journal:  Oncotarget       Date:  2015-04-30

10.  Low-dose salinomycin induces anti-leukemic responses in AML and MLL.

Authors:  Gary D R Roulston; Charlotte L Burt; Laura M J Kettyle; Kyle B Matchett; Heather L Keenan; Nuala M Mulgrew; Joanne M Ramsey; Caoifa Dougan; John McKiernan; Ivan V Grishagin; Ken I Mills; Alexander Thompson
Journal:  Oncotarget       Date:  2016-11-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.